TRANSCATHETER OCCLUSION DEVICE NON-RANDOMIZED TRIALS APPROPRIATE FOR PDA, ASD INDICATIONS; RANDOMIZATION IS FEASIBLE FOR PFO STUDIES, FDA ADVISORY PANEL SAYS
This article was originally published in The Gray Sheet
Executive SummaryManufacturers of transcatheter occlusion devices intended for treatment of patent ductus arteriosus (PDA) and atrial septal defect (ASD) should be able to conduct non-randomized trials to support FDA premarket approval, members of FDA's Circulatory System Devices Panel agreed at an Oct. 24 meeting in Gaithersburg, Maryland.
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.